Results 161 to 170 of about 2,987,019 (361)

Where, how, and how much? A multicenter cohort study of the relationship between lupus decision aid modality, place of administration, interruption and viewing completeness and patient‐reported outcomes

open access: yesArthritis Care &Research, Accepted Article.
Objective We assessed whether shared decision‐making (SDM), and patient acceptability, feasibility, and overall satisfaction with a computerized patient decision aid (PtDA) for patients with systemic lupus erythematosus (SLE), differs by PtDA setting, modality, and the viewing experience.
Jasvinder A. Singh   +3 more
wiley   +1 more source

Validity and Cost-Effectiveness of the Gonozyme Test in the Diagnosis of Gonorrhea [PDF]

open access: green, 1986
E. Thomas   +6 more
openalex   +1 more source

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

open access: yesArthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang   +4 more
wiley   +1 more source

Lived and care experiences of chronic musculoskeletal shoulder pain in Australian adults: A qualitative study

open access: yesArthritis Care &Research, Accepted Article.
Objectives Australian evidence on lived and care experiences of chronic musculoskeletal shoulder pain (CMSP), irrespective of disorder classification or disease, is limited. However, such evidence is important for person‐centred care and informing local service pathways and care guidelines or standards.
Sonia Ranelli   +8 more
wiley   +1 more source

Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany

open access: yesCost Effectiveness and Resource Allocation
Background Triple-negative breast cancer (TNBC) is responsible for 10–20% cases of breast cancer and is resulting in rising healthcare costs. Thus, health-economic evaluations are needed to relate clinical outcomes and costs of treatment options and to ...
Amelie Wickmann   +6 more
doaj   +1 more source

What are the “costs” of cost-effectiveness? [PDF]

open access: yesThe Journal of Thoracic and Cardiovascular Surgery, 2018
openaire   +3 more sources

Home - About - Disclaimer - Privacy